Aurora Cannabis Inc. Files 6-K with Updated News Release

TL;DR

Aurora Cannabis filed a 6-K to fix errors in a July 25th press release. No new info, just cleanup.

AI Summary

Aurora Cannabis Inc. filed an updated Form 6-K on July 26, 2024, to correct textual errors in its news release dated July 25, 2024. The filing is an amendment to a previous report and does not introduce new financial information but rather refines existing disclosures.

Why It Matters

This filing indicates a procedural update to correct minor errors in previously issued public information, suggesting a focus on accuracy in disclosures by Aurora Cannabis.

Risk Assessment

Risk Level: low — The filing is a procedural correction of a previous news release and does not contain new material financial information or strategic changes.

Key Players & Entities

• Aurora Cannabis Inc. (company) — Registrant
• July 25, 2024 (date) — Date of original news release
• July 26, 2024 (date) — Filing date of Form 6-K
• Miguel Martin (person) — Signatory for Aurora Cannabis Inc.

FAQ

From the Filing

0000950142-24-002011.txt : 20240726 0000950142-24-002011.hdr.sgml : 20240726 20240725195850 ACCESSION NUMBER: 0000950142-24-002011 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240725 FILED AS OF DATE: 20240726 DATE AS OF CHANGE: 20240725 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 241143322 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 eh240512751_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ EXPLANATORY NOTE This current report on Form 6-K is being furnished with an updated version of Exhibit 99.1, the news release dated July 25, 2024, which corrects certain textual errors contained therein. SUBMITTED HEREWITH Exhibits Description 99.1 News Release dated July 25, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: July 25, 2024 EX-99.1 2 eh240512751_ex9901.htm EXHIBIT 99.1 EXHIBIT 99.1 July 25, 2024 NASDAQ | TSX: ACB Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility Company’s Long-Standing Investment in the Region Continues with Enhanced Local Production and Domestic Cultivar Research Edmonton, AB – July 25, 2024 – Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ | TSX: ACB), a leading Canadian-based global medical cannabis company, has been granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's new Medical Cannabis Act (MedCanG). Aurora’s license grants the company continued domestic cultivation, which has been underway for two years now. Under the new license, Aurora may also cultivate an approved additional product, and plans to expand their offerings to the rapidly growing German patient base. Aurora will also receive a dedicated R&D license, allowing for the trial of up to seven additional novel cultivars at the company’s local EU GMP facility in Leuna, Germany. “We thank the German government for its continued investment in the growth of medical cannabis, made possible by decriminalization, which will improve access to medical cannabis for patients all across Germany,” says Michael Simon, President, Aurora Europe. “Being one of the few companies to receive enhanced licenses is a testament to Aurora’s established leadership in the region and unparalleled commitment to making available the highest quality cannabis. We now have the framework to extend our portfolio, invest in domestic research and leverage Aurora’s global cultivation expertise locally.” Aurora is committed to the growth, acceptance and broader access to medical cannabis globally. The company's leadership in Europe is a result of ongoing collaboration with government, regulators and industry. Sin